🕒 Last update: loading…

Stock Inovio Pharmaceuticals, Inc. INO

Inovio Pharmaceuticals, Inc. — Investlytic score 2/5 on the five criteria.

-
-
40/ 100
Score Investlytic · 5 criteria

Analysis in progress…

Investlytic score: 2/5 criteria met.

  • ❌ Price trend failed
  • ❌ Growth failed
  • ✅ Debt passed
  • ❌ P/E failed
  • ✅ Correction passed

Price trend

Overall trend (8 years): insufficient progression (less than x1.5).

Price change 2018 → 2019: -17.50%

Price change 2019 → 2020: 168.18%

Price change 2020 → 2021: -43.62%

Price change 2021 → 2022: -68.74%

Price change 2022 → 2023: -67.31%

Price change 2023 → 2024: -70.10%

Price change 2024 → 2025: -4.92%

Price change 2025 → 2026: -30.46%

Price change 2026 (year to date): -28.40%

Financial growth

Revenue CAGR (8 years): -58.43%

Earnings CAGR (8 years): N/A

Growth status: insufficient data or negative trend.

Debt

Debt-to-equity ratio: 0.39

Debt/equity < 0.5 (maximum threshold).

P/E (Price/Earnings)

P/E ratio: -1.00

P/E > 25.0 (maximum threshold).

Correction (6 months)

Current correction: 17.12% from the high over 6 months.

Correction between 10.0% and 20.0% (target range).

WATCH
The stock is currently being evaluated.

Criteria of the Investlytic model

- / 5
🔒

Investlytic rating reserved for members

Score out of 100, mechanical verdict of the method (hold, watch, sell: the same for all) and the detail of the 5 criteria · visible with a free account.

02

Price trend

Price & trend

Interactive chart →
Loading chart…

⚖️ Comparison with the market

All stocks →
StockP/EDette/FPRevenue growthRating
Inovio Pharmaceuticals, Inc.–0.39−26.1 %🔒
Organogenesis Holdings Inc.27.00.31––
Guerbet S.A.–1.64+5.5 %–
Neuronetics, Inc.–4.04+17.8 %–
Onward Medical N.V.–0.25+34.5 %–

Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.

03

Detailed analysis · Price trend

-

🔒

Reserved for members

Global model trend and annual price variations · visible with a free account.

04

Revenues & profits

Revenue and net income

🔒

Reserved for members

Chart of revenues and net income over 8 periods · real data, no estimates.

05

Financial indicators

🔒

Reserved for members

18 financial indicators analyzed by groups of criteria: valuation, profitability, growth, solidity, dividend, and momentum.

06

Annual financial statements

Fiscal yearRevenueNet income Net marginEPSRevenue growth
🔒

Reserved for members

Complete annual financial statements: revenue, net income, margin, and EPS over 8 fiscal years.

+

Key reported figures

Revenue, net income and net margin reported by Inovio Pharmaceuticals, Inc. over the latest fiscal years.

Revenue
65,343 USD
fiscal year 2025
Net income
-84.9 m USD
fiscal year 2025
Net margin
-130,000.0 %
fiscal year 2025
Average annual growth
-61.2 %
Revenue growth over 5 years
Average annual growth
-47.4 %
Revenue growth over 10 years
Market cap
98.8 m USD
Fiscal yearRevenueNet incomeNet marginRevenue growth
20207.4 m-166 m-2,245.4 %n/a
20211.8 m-304 m-17,109.9 %-76.1 %
202210.3 m-280 m-2,726.7 %+478.2 %
2023832,010-135 m-16,239.9 %-91.9 %
2024217,756-107 m-49,254.3 %-73.8 %
202565,343-84.9 m-130,000.0 %-70.0 %

Amounts converted to USD. Source: published annual accounts, collected on 13/11/2026.

+

Accounts and financial health

Balance sheet and cash flow published by Inovio Pharmaceuticals, Inc. over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).

Overview
fragile accounts
according to Altman Z, Piotroski and net debt
Altman Z-score
-47.91
risk zone (below 1.81)
Piotroski Score
2 / 9
0 to 3: fragile accounts
DCF Value
0.690 USD
DCF below share price · share price 1.65 USD, gap -57.9 %
Net Debt / EBITDA
0.58 x
low debt
Fiscal year20212022202320242025
Cash and investments401 m253 m145 m94.1 m58.5 m
Total Debt33.0 m32.1 m30.2 m11.9 m9.4 m
Net Debt-38.1 m-14.3 m15.9 m-53.9 m-34.9 m
Equity400 m222 m117 m68.5 m24.1 m
Total assets496 m349 m171 m113 m74.3 m
Operating cash flow-216 m-216 m-124 m-104 m-88.6 m
Investments (capex)1.2 m969,153320,898487,832285,698
Free cash-flow-217 m-217 m-125 m-105 m-88.9 m
Share buybacks00000
Dividends paid00000

Amounts in USD, currency of the published accounts.

Trailing 12-month ratios

Price / earnings (P/E)-2.15 x
Price / book value-4.97 x
Return on Equity (ROE)-46,473.1 %
Return on Invested Capital (ROIC)291.2 %
Net margin-23,798.9 %
Debt / equity-0.21 x
Current ratio0.57 x
Free cash-flow yield-63.0 %

Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 20/11/2026.

+

Analyst consensus and forecasts

What the financial analysts covering Inovio Pharmaceuticals, Inc. publish: ratings, price targets and earnings forecasts.

Majority rating
buy
17 analysts

Breakdown of ratings

strong buy 0buy 11hold 4sell 2strong sell 0

Price targets: published for companies listed in the United States only.

Track record against expectations: reported EPS above consensus 8 times over the last 12 releases.

Source: ratings and forecasts published by analysts, collected on 21/11/2026. An analyst rating or target is not a guarantee.

+

PEA and practical information

PEA eligibility
no
head office outside the EU and EEA
Listing exchange
Nasdaq
IPO: 08/12/1998
ISIN code
US45773H4092
Workforce
134
full-time employees
Chief executive
Jacqueline E. Shea

Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.

?

Frequently asked questions about Inovio Pharmaceuticals, Inc.

What is the Inovio Pharmaceuticals, Inc. share price?

Latest recorded price: 1.43 USD on 13/11/2026, for a market cap of 98.8 m USD.

What is the revenue of Inovio Pharmaceuticals, Inc.?

65,343 USD for fiscal year 2025, with net income of -84.9 m USD (net margin -130,000.0 %).

What do analysts say about Inovio Pharmaceuticals, Inc.?

Out of 17 analysts: 11 buy or strong buy, 4 hold, 2 sell or strong sell.

Is Inovio Pharmaceuticals, Inc. stock eligible for the French PEA?

No: the company is headquartered outside the European Union and the European Economic Area (ISIN US45773H4092).

How many employees does Inovio Pharmaceuticals, Inc. have?

134 full-time employees according to the latest published profile.

Who runs Inovio Pharmaceuticals, Inc.?

Jacqueline E. Shea is the company's chief executive.

07

Similar stocks